Ziv Rosman

Dr. Ziv Rosman

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2013 in BMC Medicine
Verified
Journal Article
Open access
PDF file
ZRZiv Rosman
Ziv Rosman
Yehuda ShoenfeldYehuda Shoenfeld
Yehuda Shoenfeld
GZGisele Zandman-Goddard
Gisele Zandman-Goddard
Biologic therapies for rheumatologic diseases, which are targeted at molecules involved in the mechanisms of the immune system, provide an alternative to the existing treatment methods of disease-modifying anti-rheumatic drugs and other immunosuppressive medications. However, the current drawbacks of biologic therapies, including the inconvenience of intravenous administration, the high costs of these drugs, and the adverse events associated with them, prevent their wide use as first-line medications. This review provides an update of the recent literature on the new biologic therapies available. The review concentrates on nine drugs: tocilizumab, rituximab, ofatumumab, belimumab, epratuzumab, abatacept, golimumab, certolizumab, and sifalimumab, which are used as therapies for rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, systemic sclerosis, or vasculitis.

10 September 2014
Verified
Book Chapter
Closed access
PDF file
ZRZiv Rosman
Ziv Rosman
Yehuda ShoenfeldYehuda Shoenfeld
Yehuda Shoenfeld
GZGisele Zandman-Goddard
Gisele Zandman-Goddard

24 October 2024 in Infectious Disease Reports
Verified
Journal Article
Open access
PDF file
ZRZiv Rosman
Ziv Rosman
Yasmin MaorYasmin Maor
Yasmin Maor
IZIris Zohar
Iris Zohar
RBRonen Gingy Balmor
Ronen Gingy Balmor
MPMiri Schamroth Pravda
Miri Schamroth Pravda
ASArie Soroksky
Arie Soroksky
Sepsis is a life-threatening organ dysfunction syndrome caused by a dysregulated host response to infection that has a high mortality rate. Proprotein convertase subtilisin kexin 9 (PCSK9) is a serine protease secreted by the liver. Its binding to the low-density lipoprotein (LDL) receptor enhances its degradation, causing an increase in LDL levels in the blood. Objectives: Administering a PCSK9 inhibitor leading to an increase in lipid uptake by the liver may positively affect septic patients due to the increased removal of endotoxins. Methods: This preliminary study aimed to examine the safety of PCSK9 inhibitor use in septic and septic shock patients. We treated five septic patients in the intensive care unit with 300 mg of alirocumab following serious adverse events for 28 days. Results: Four of our patients did not experience any adverse events, and all of them survived. One patient died after discharge from the intensive care unit, and this death was presumably not related to the study drug. The patients rapidly recovered from the inflammatory stage of sepsis. Conclusions: Alirocumab appears safe in severe sepsis and septic shock patients. The outcome data are promising. Only a basic safety profile can be assessed based on this pilot study. Further study with a PCSK-9 inhibitor in septic or septic shock patients is required to further determine its benefit in ICU patients.